Abcellera Biologics Inc (ABCL) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

ABCL

2.79

USD-0.21-7.15%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Latest News

@DeItaone

1 year

Coverage Initiated $ABCL $ACLS $AMTX $CLNE $GPCR $IDYA $IRON $MGTA $NRIX $OPAL $TCOM https://t.co/HsvywOztkC https://t.co/bbmUsfp2qf

Seeking Alpha

3 years

ABCL, TCRR, KYMR and GRTS among after hours movers

@eWhispers

3 years

Bigger-than-usual #earnings moves today from $HNST $EAR $ABCL $TTCF $PAVM $AGRO $SEER $ERJ $PVG $FLO $CRMD $KMPH $AEVA $AFIB $RKT $PRPH $WISH $VIAV https://t.co/1pgojKC5HH https://t.co/Jm0tvO5aE9

@eWhispers

3 years

#earnings after the close https://t.co/lObOE0dgsr $DIS $WISH $ABNB $SOFI $RKT $SNDL $DASH $TTCF $GEVO $LAZR $CODX $BW $ABCL $RSI $KMPH $CRCT $WPM $LIVX $BEEM $BLFS $MAXN $GLOB $BLBD $IZEA $VIAV $BIOL $FLO $LFMD $SWIR $AFIB $AEVA $PTE $ZIP $AVIR $PHUN $FIGS $APDN $AGTI $YCBD https://t.co/Ublw8dMJNv

Seeking Alpha

3 years

STAA, SCR, GMTX and ABCL among after-hours movers

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

2.76USD

3.06USD

52 Week Range

2.33USD

5.62USD

Market Cap

862.47MUSD

Billionaire Owners

Get Full Access with Profit PRO

See which Billionaires own this investment

About

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

CA00288U1066

CUSIP

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

3.65

Dividend Share

Dividend Yield

Earnings Share

-0.61

Wall Street Target Price

12.1429

EPS Estimate Current Year

-0.5929

EPS Estimate Next Year

-0.675

EPS Estimate Current Quarter

-0.15

EPS Estimate Next Quarter

-0.16

Most Recent Quarter

Profitability

Revenue TTM

32,962,000

Gross Profit TTM

-136,843,008

EBITDA

-222,243,008

Profit Margin

0.00%

Return On Assets TTM

-13.26%

Return On Equity TTM

-15.55%

Revenue Per Share TTM

0.112

Qtly Revenue Growth YOY

-1.40%

Diluted Eps TTM

-0.61

Qtly Earnings Growth YOY

45.90%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

26.8824

Price Book MRQ

0.8219

Enterprise Value Revenue

Enterprise Value EBITDA

Peers analysis

CMXHFCSL Limited
169.54
3.19%
CSLLYCSL Ltd
86.83
0.51%
ARGNFargenx SE
655.00
0.00%
UCBJFUCB SA
194.85
0.00%
ALNYAlnylam Pharmaceuticals Inc
240.51
-7.01%

REGNRegeneron Pharmaceuticals Inc
694.00
-3.22%
BNTXBioNTech SE
112.43
-1.09%
ARGXargenx NV ADR
665.60
-0.72%
VRTXVertex Pharmaceuticals Inc
412.28
-0.27%
UCBJYUCB SA ADR
97.63
-0.27%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2025